It has been suggested that the plasma NPY level could be used as an early diagnostic marker for pheochromocytomas and paragangliomas in patients who received treatments that interfere with catecholamine reuptake or suffer from severe kidney impairment [224]. Here, NPY is linked to hereditary pheochromocytoma-paraganglioma.